Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PoC study of SAR440340/REGN3500 with or without dupilumab in adults with asthma
2017-003289-29Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing SAR440340/REGN3500 monotherapy, SAR440340/REGN3500 + dupilumab and Placebo (3 arms). Primary endpoint: Loss of asthma control (LOAC) events. Started Apr 2018; status: completed.
02
Drugs
itepekimabdupilumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-003289-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003289-29.